대한뉴팜

Daehan Nupharm recorded KRW 102.4 billion in sales, KRW 10.8 billion in operating profit, and KRW 10.8 billion in net profit for the second quarter of 2024, continuing its solid profitability trend.
 

The strong performance was largely driven by stable growth in the company’s core pharmaceutical business, particularly the successful launch of its gastroesophageal reflux disease (GERD) treatment, Rapiduo Tab. Actively promoted since its release, Rapiduo Tab. combines rabeprazole (PPI) with magnesium oxide, achieving peak plasma concentration within one hour, significantly faster than existing PPI formulations (6~7 hours), thereby overcoming a key limitation of conventional products.

In parallel with its commercial success, Daehan Nupharm is expanding its R&D pipeline through specialized research organizations, including the Central Research Institute for human pharmaceuticals, the Biotech Research Institute for biopharmaceuticals, and the Animal Health Research Institute for veterinary medicines.

The Central Research Institute plans to add a high-dose 20/350 mg formulation of Rapiduo Tab., while also conducting active research on improved combination drugs for hypertension, hyperlipidemia, and obesity. The Biotech Research Institute is working with domestic biotech companies and overseas research institutes to develop antiviral therapies. Meanwhile, the Animal Health Research Institute has achieved notable milestones, including the 2023 launch of Teramin Tab. (terbinafine) and the world’s first fluconazole formulation for companion dogs, DH Fuzole Tab., launched in June 2024, following earlier development of the human formulation, Fuzole Tab.

Beyond R&D investment, Daehan Nupharm is constructing a new GMP production facility to enhance its manufacturing capacity. The new plant will be equipped with state-of-the-art production systems to ensure the large-scale supply of high-quality pharmaceuticals.